2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole profile

2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole: an amyloid imaging agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2826731
CHEMBL ID	207456
SCHEMBL ID	2055285
MeSH ID	M0451542
PubMed CID	10171487
CHEMBL ID	93124
SCHEMBL ID	912744
MeSH ID	M0451542

Synonym
pittsburgh compound b
n-methyl-[11c]-2-(4 -methylaminophenyl)-6-hydroxybenzothiasole
[11C]6-OH-BTA-1
[11c]pittsburgh compound-b
[11c]pib
CHEMBL207456
pib c-11
pittsburgh compound b c-11
(11c)pib
7p55415b0r ,
c-11 pib
566170-04-5
unii-7p55415b0r
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
pittsburgh b
11c-pib
(n-methyl-(11c))2-(4'-methylaminophenyl)-6-hydroxybenzothiazole
6-benzothiazolol, 2-(4-(methyl-11c-amino)phenyl)-
SCHEMBL2055285
DTXSID00205194
Q4047010
DB15161
2-[4-((111c)methylamino)phenyl]-1,3-benzothiazol-6-ol
CHEMBL93124 ,
2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
6-hydroxy-2-(4''''-n-methylaminophenyl)-1,3-benzothiazole
bdbm50129793
[3h]2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol
2-(4-methylamino-phenyl)-benzothiazol-6-ol
2-(4''''-methylaminophenyl)-6-hydroxybenzothiazole
4-methylamino-phenyl)-benzothiazol-6-ol
n-methyl-2-(4''''-methylaminophenyl)-6-hydroxybenzothiazole
n-methyl-[11c]2-(40-methylaminophenyl)-6-hydroxy benzothiazole
2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol
pittsburgh compound b unlabelled
2-(4'-methylaminophenyl)-6-hydroxybenzothiazole
K6396E6G8G ,
566169-93-5
2-[4-(n-monomethyl)aminophenyl]-6-hydroxybenzothiazole
ZQAQXZBSGZUUNL-UHFFFAOYSA-N
AKOS022184240
SCHEMBL912744
mfcd17018727
unii-k6396e6g8g
IZV ,
EX-A7898B
2-[4-(methylamino)phenyl]benzo[d]thiazol-6-ol
AMY9948
6-oh-bta-1
Y11631
Q27282003
CS-0092545
2-[4-(methylamino)phenyl]benzothiazol-6-ol
SY274908
2-(4'-aminophenyl)-6-hydroxybenzo-thiazole

Excerpt	Reference	Relevance
"The scanning process was feasible and acceptable with no adverse events or safety concerns."	( Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Aigbirhio, FI; Baron, JC; Canales, R; D'Abrera, JC; Fryer, TD; Holland, AJ; Hong, YT; Landt, J; Menon, DK; Zaman, SH, 2011)	0.37

Excerpt	Reference	Relevance
"Based on its pharmacokinetic profile, [(18)F]flutemetamol showed potential as a PET tracer for preclinical imaging."	( Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eskola, O; Farrar, G; Haaparanta-Solin, M; Lopez-Picon, FR; Rinne, JO; Rokka, J; Scheinin, M; Snellman, A; Solin, O; Wilson, I, 2012)	0.38
" Here, we report the preparation and pharmacokinetic profile of its carbon-11 (t1/2 = 20."	( Synthesis, radiolabeling, and in vivo pharmacokinetic evaluation of the amyloid beta radioligand [11C]AZD4694 in nonhuman primates. Amini, N; Bergman, L; Cselenyi, Z; Farde, L; Gulyas, B; Halldin, C; Johnström, P; Lindström-Böö, E; Nakao, R; Sandell, J; Schou, M; Sumic, A; Svensson, S; Varnäs, K, 2014)	0.4
"The advantageous pharmacokinetic profile and low nonspecific binding render [(11)C]AZD4694 a promising PET radioligand for imaging of amyloid beta in the human brain with PET."	( Synthesis, radiolabeling, and in vivo pharmacokinetic evaluation of the amyloid beta radioligand [11C]AZD4694 in nonhuman primates. Amini, N; Bergman, L; Cselenyi, Z; Farde, L; Gulyas, B; Halldin, C; Johnström, P; Lindström-Böö, E; Nakao, R; Sandell, J; Schou, M; Sumic, A; Svensson, S; Varnäs, K, 2014)	0.4

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Amyloid-beta precursor protein	Homo sapiens (human)	Ki	0.0088	0.0001	0.0856	0.8900	AID265144; AID656661; AID656662; AID673978; AID748694; AID769548
Amyloid-beta precursor protein	Homo sapiens (human)	IC50 (µMol)	0.0190	0.0005	3.8895	10.0000	AID671384
Amyloid-beta precursor protein	Homo sapiens (human)	Ki	0.1426	0.0001	0.0856	0.8900	AID1179999; AID1273178; AID38663; AID445593; AID459782; AID574648; AID574649
Microtubule-associated protein tau	Homo sapiens (human)	IC50 (µMol)	3.2550	0.0690	1.9769	3.5000	AID718586
Sulfotransferase 1A1	Homo sapiens (human)	Ki	0.0051	0.0051	0.0120	0.0190	AID1639858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sulfotransferase 1E1	Homo sapiens (human)	Km	1.6000	1.6000	4.6367	6.4000	AID1639871
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of autophagy	Microtubule-associated protein tau	Homo sapiens (human)
microtubule cytoskeleton organization	Microtubule-associated protein tau	Homo sapiens (human)
microglial cell activation	Microtubule-associated protein tau	Homo sapiens (human)
internal protein amino acid acetylation	Microtubule-associated protein tau	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Microtubule-associated protein tau	Homo sapiens (human)
DNA damage response	Microtubule-associated protein tau	Homo sapiens (human)
cell-cell signaling	Microtubule-associated protein tau	Homo sapiens (human)
memory	Microtubule-associated protein tau	Homo sapiens (human)
response to lead ion	Microtubule-associated protein tau	Homo sapiens (human)
negative regulation of gene expression	Microtubule-associated protein tau	Homo sapiens (human)
negative regulation of mitochondrial membrane potential	Microtubule-associated protein tau	Homo sapiens (human)
rRNA metabolic process	Microtubule-associated protein tau	Homo sapiens (human)
axonal transport of mitochondrion	Microtubule-associated protein tau	Homo sapiens (human)
central nervous system neuron development	Microtubule-associated protein tau	Homo sapiens (human)
regulation of microtubule polymerization or depolymerization	Microtubule-associated protein tau	Homo sapiens (human)
regulation of microtubule polymerization	Microtubule-associated protein tau	Homo sapiens (human)
positive regulation of microtubule polymerization	Microtubule-associated protein tau	Homo sapiens (human)
cytoplasmic microtubule organization	Microtubule-associated protein tau	Homo sapiens (human)
neuron projection development	Microtubule-associated protein tau	Homo sapiens (human)
positive regulation of superoxide anion generation	Microtubule-associated protein tau	Homo sapiens (human)
regulation of chromosome organization	Microtubule-associated protein tau	Homo sapiens (human)
negative regulation of kinase activity	Microtubule-associated protein tau	Homo sapiens (human)
stress granule assembly	Microtubule-associated protein tau	Homo sapiens (human)
cellular response to heat	Microtubule-associated protein tau	Homo sapiens (human)
cellular response to reactive oxygen species	Microtubule-associated protein tau	Homo sapiens (human)
positive regulation of axon extension	Microtubule-associated protein tau	Homo sapiens (human)
microtubule polymerization	Microtubule-associated protein tau	Homo sapiens (human)
astrocyte activation	Microtubule-associated protein tau	Homo sapiens (human)
regulation of synaptic plasticity	Microtubule-associated protein tau	Homo sapiens (human)
intracellular distribution of mitochondria	Microtubule-associated protein tau	Homo sapiens (human)
generation of neurons	Microtubule-associated protein tau	Homo sapiens (human)
synapse organization	Microtubule-associated protein tau	Homo sapiens (human)
regulation of calcium-mediated signaling	Microtubule-associated protein tau	Homo sapiens (human)
protein polymerization	Microtubule-associated protein tau	Homo sapiens (human)
axon development	Microtubule-associated protein tau	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Microtubule-associated protein tau	Homo sapiens (human)
plus-end-directed organelle transport along microtubule	Microtubule-associated protein tau	Homo sapiens (human)
regulation of mitochondrial fission	Microtubule-associated protein tau	Homo sapiens (human)
negative regulation of mitochondrial fission	Microtubule-associated protein tau	Homo sapiens (human)
supramolecular fiber organization	Microtubule-associated protein tau	Homo sapiens (human)
axonal transport	Microtubule-associated protein tau	Homo sapiens (human)
regulation of cellular response to heat	Microtubule-associated protein tau	Homo sapiens (human)
regulation of long-term synaptic depression	Microtubule-associated protein tau	Homo sapiens (human)
positive regulation of protein localization to synapse	Microtubule-associated protein tau	Homo sapiens (human)
neurofibrillary tangle assembly	Microtubule-associated protein tau	Homo sapiens (human)
negative regulation of establishment of protein localization to mitochondrion	Microtubule-associated protein tau	Homo sapiens (human)
positive regulation of protein localization	Microtubule-associated protein tau	Homo sapiens (human)
negative regulation of tubulin deacetylation	Microtubule-associated protein tau	Homo sapiens (human)
positive regulation of diacylglycerol kinase activity	Microtubule-associated protein tau	Homo sapiens (human)
amyloid fibril formation	Microtubule-associated protein tau	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Microtubule-associated protein tau	Homo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulus	Microtubule-associated protein tau	Homo sapiens (human)
sulfation	Sulfotransferase 1E1	Homo sapiens (human)
ethanol catabolic process	Sulfotransferase 1E1	Homo sapiens (human)
estrogen catabolic process	Sulfotransferase 1E1	Homo sapiens (human)
steroid metabolic process	Sulfotransferase 1E1	Homo sapiens (human)
estrogen metabolic process	Sulfotransferase 1E1	Homo sapiens (human)
positive regulation of fat cell differentiation	Sulfotransferase 1E1	Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic process	Sulfotransferase 1E1	Homo sapiens (human)
sulfation	Sulfotransferase 1E1	Homo sapiens (human)
sulfation	Sulfotransferase 1A1	Homo sapiens (human)
ethanol catabolic process	Sulfotransferase 1A1	Homo sapiens (human)
catecholamine metabolic process	Sulfotransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	Sulfotransferase 1A1	Homo sapiens (human)
estrogen metabolic process	Sulfotransferase 1A1	Homo sapiens (human)
amine metabolic process	Sulfotransferase 1A1	Homo sapiens (human)
flavonoid metabolic process	Sulfotransferase 1A1	Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate metabolic process	Sulfotransferase 1A1	Homo sapiens (human)
sulfation	Sulfotransferase 1A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Microtubule-associated protein tau	Homo sapiens (human)
minor groove of adenine-thymine-rich DNA binding	Microtubule-associated protein tau	Homo sapiens (human)
double-stranded DNA binding	Microtubule-associated protein tau	Homo sapiens (human)
single-stranded DNA binding	Microtubule-associated protein tau	Homo sapiens (human)
RNA binding	Microtubule-associated protein tau	Homo sapiens (human)
actin binding	Microtubule-associated protein tau	Homo sapiens (human)
protein binding	Microtubule-associated protein tau	Homo sapiens (human)
microtubule binding	Microtubule-associated protein tau	Homo sapiens (human)
SH3 domain binding	Microtubule-associated protein tau	Homo sapiens (human)
enzyme binding	Microtubule-associated protein tau	Homo sapiens (human)
protein kinase binding	Microtubule-associated protein tau	Homo sapiens (human)
protein-macromolecule adaptor activity	Microtubule-associated protein tau	Homo sapiens (human)
apolipoprotein binding	Microtubule-associated protein tau	Homo sapiens (human)
dynactin binding	Microtubule-associated protein tau	Homo sapiens (human)
phosphatidylinositol binding	Microtubule-associated protein tau	Homo sapiens (human)
identical protein binding	Microtubule-associated protein tau	Homo sapiens (human)
sequence-specific DNA binding	Microtubule-associated protein tau	Homo sapiens (human)
protein-folding chaperone binding	Microtubule-associated protein tau	Homo sapiens (human)
protein phosphatase 2A binding	Microtubule-associated protein tau	Homo sapiens (human)
Hsp90 protein binding	Microtubule-associated protein tau	Homo sapiens (human)
lipoprotein particle binding	Microtubule-associated protein tau	Homo sapiens (human)
histone-dependent DNA binding	Microtubule-associated protein tau	Homo sapiens (human)
microtubule lateral binding	Microtubule-associated protein tau	Homo sapiens (human)
phosphatidylinositol bisphosphate binding	Microtubule-associated protein tau	Homo sapiens (human)
estrone sulfotransferase activity	Sulfotransferase 1E1	Homo sapiens (human)
steroid binding	Sulfotransferase 1E1	Homo sapiens (human)
protein binding	Sulfotransferase 1E1	Homo sapiens (human)
sulfotransferase activity	Sulfotransferase 1E1	Homo sapiens (human)
flavonol 3-sulfotransferase activity	Sulfotransferase 1E1	Homo sapiens (human)
steroid sulfotransferase activity	Sulfotransferase 1E1	Homo sapiens (human)
aryl sulfotransferase activity	Sulfotransferase 1E1	Homo sapiens (human)
aryl sulfotransferase activity	Sulfotransferase 1A1	Homo sapiens (human)
protein binding	Sulfotransferase 1A1	Homo sapiens (human)
sulfotransferase activity	Sulfotransferase 1A1	Homo sapiens (human)
flavonol 3-sulfotransferase activity	Sulfotransferase 1A1	Homo sapiens (human)
steroid sulfotransferase activity	Sulfotransferase 1A1	Homo sapiens (human)
3'-phosphoadenosine 5'-phosphosulfate binding	Sulfotransferase 1A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
microtubule	Microtubule-associated protein tau	Homo sapiens (human)
membrane	Microtubule-associated protein tau	Homo sapiens (human)
extracellular region	Microtubule-associated protein tau	Homo sapiens (human)
nucleus	Microtubule-associated protein tau	Homo sapiens (human)
cytoplasm	Microtubule-associated protein tau	Homo sapiens (human)
mitochondrion	Microtubule-associated protein tau	Homo sapiens (human)
cytosol	Microtubule-associated protein tau	Homo sapiens (human)
plasma membrane	Microtubule-associated protein tau	Homo sapiens (human)
microtubule cytoskeleton	Microtubule-associated protein tau	Homo sapiens (human)
nuclear speck	Microtubule-associated protein tau	Homo sapiens (human)
axon	Microtubule-associated protein tau	Homo sapiens (human)
dendrite	Microtubule-associated protein tau	Homo sapiens (human)
growth cone	Microtubule-associated protein tau	Homo sapiens (human)
axolemma	Microtubule-associated protein tau	Homo sapiens (human)
nuclear periphery	Microtubule-associated protein tau	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Microtubule-associated protein tau	Homo sapiens (human)
somatodendritic compartment	Microtubule-associated protein tau	Homo sapiens (human)
neuronal cell body	Microtubule-associated protein tau	Homo sapiens (human)
dendritic spine	Microtubule-associated protein tau	Homo sapiens (human)
cell body	Microtubule-associated protein tau	Homo sapiens (human)
main axon	Microtubule-associated protein tau	Homo sapiens (human)
membrane raft	Microtubule-associated protein tau	Homo sapiens (human)
glial cell projection	Microtubule-associated protein tau	Homo sapiens (human)
neurofibrillary tangle	Microtubule-associated protein tau	Homo sapiens (human)
axon cytoplasm	Microtubule-associated protein tau	Homo sapiens (human)
tubulin complex	Microtubule-associated protein tau	Homo sapiens (human)
neuron projection	Microtubule-associated protein tau	Homo sapiens (human)
cytosol	Sulfotransferase 1E1	Homo sapiens (human)
nuclear membrane	Sulfotransferase 1E1	Homo sapiens (human)
cytoplasm	Sulfotransferase 1E1	Homo sapiens (human)
cytosol	Sulfotransferase 1A1	Homo sapiens (human)
cytoplasm	Sulfotransferase 1A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (338)

Assay ID	Title	Year	Journal	Article
AID439188	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 47.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347554	Biodistribution in NMRI mouse heart at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID347578	Metabolic stability in NMRI mouse brain assessed as intact drug level at 5.55 MBq, iv after 2 mins by RP-HPLC analysis	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438934	Drug level in NMRI mouse spleen/pancreas assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439666	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 37.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439659	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 10 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438956	Drug level in NMRI mouse cerebrum assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439657	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 6 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438939	Biodistribution in NMRI mouse lung assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID443214	Biostability in normal rhesus monkey assessed as intact drug level in plasma at 9 MBq, iv after 30 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID369064	Displacement of [125I]IMPY from beta-amyloid plaques in Alzheimer's disease patient brain homogenate	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB.
AID439192	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 75 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439646	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 47.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439636	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 8 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438941	Drug level in NMRI mouse lung assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439182	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 17.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID656739	Metabolic stability in Balb-C mouse blood at 21 to 32 MBq, iv after 30 mins by gamma counting	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID439170	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 75 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439166	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 47.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439168	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 57.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439189	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 52.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347548	Biodistribution in NMRI mouse spleen/pancreas assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438965	Biodistribution in NMRI mouse blood at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439137	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 14 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347543	Biodistribution in NMRI mouse liver assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID769547	Drug uptake in baboon brain measured at 2 mins	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID656740	Metabolic stability in Balb-C mouse brain at 21 to 32 MBq, iv after 10 mins by gamma counting	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID439648	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 57.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439662	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 17.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID772426	Binding affinity to human tau associated NFTs at 100 uM by fluorescence microscopy	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Imaging probes of tau pathology.
AID347533	Displacement of [125I]IMPY from beta-amyloid plaques in Alzheimer's disease patient brain homogenate	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439173	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 1.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438942	Biodistribution in NMRI mouse heart at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347541	Biodistribution in NMRI mouse liver at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438968	Drug level in NMRI mouse blood assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347556	Biodistribution in NMRI mouse heart assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439178	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 8 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439661	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 14 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347564	Biodistribution in NMRI mouse cerebrum assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439631	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 1.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438953	Biodistribution in NMRI mouse cerebrum at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438940	Drug level in NMRI mouse lung assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347551	Biodistribution in NMRI mouse lung assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439148	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 75 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347569	Biodistribution in NMRI mouse blood at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439144	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 47.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID574655	Drug uptake in Balb-C mouse brain assessed as compound remaining at 4-6 MBq after 30 mins by gamma counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID438962	Drug level in NMRI mouse cerebellum assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID475397	Octanol-water partition coefficient, log P by reverse phase HPLC method	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	[(11)C]Dimebon, radiosynthesis and lipophilicity of a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease.
AID347561	Biodistribution in NMRI mouse cerebrum at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID769548	Displacement of [N-methyl-3H]BTA-1 from amyloid beta (1 to 40) fibrils (unknown origin)	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID439694	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 75 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439635	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 6 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID622921	Ratio of drug uptake in hippocampus to cerebellum in transgenic Tg2576 mouse brain	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and evaluation of 1-(4-[¹⁸F]fluoroethyl)-7-(4'-methyl)curcumin with improved brain permeability for β-amyloid plaque imaging.
AID439163	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 32.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439652	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 0.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID594160	Displacement of [3H]BTA-1 from amyloid beta 1 to 40 by competitive binding assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain.
AID438926	Biodistribution in NMRI mouse liver assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439682	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 12 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID574654	Drug uptake in Balb-C mouse brain assessed as compound remaining at 4-6 MBq after 10 mins by gamma counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID347573	Blood clearance in NMRI mouse assessed ratio of %ID in blood after 2 mins to %ID in blood after 60 mins at 3.7 MBq/mL, iv	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439181	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 14 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID388989	Half life in human	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	[(18)F]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils.
AID347579	Metabolic stability in NMRI mouse brain assessed as intact drug level at 5.55 MBq, iv after 60 mins by RP-HPLC analysis	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID656663	Drug uptake in Balb-C mouse brain at 4 to 6 MBq, iv after 5 mins by gamma counting relative to [11C]Pittsburgh compound B	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID439190	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 57.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347538	Biodistribution in NMRI mouse kidney at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438918	Biodistribution in NMRI mouse kidney at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347542	Biodistribution in NMRI mouse liver at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439676	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 2.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439672	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 75 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439647	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 52.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439149	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 85 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347540	Biodistribution in NMRI mouse kidney assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439154	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 4.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347544	Biodistribution in NMRI mouse liver assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438960	Biodistribution in NMRI mouse cerebellum assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID656660	Ratio of drug uptake in Alzheimer's disease patient brain to healthy human brain	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID439150	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 0.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439658	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 8 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439157	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 10 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438966	Biodistribution in NMRI mouse blood assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439651	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 85 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439674	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 0.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438933	Biodistribution in NMRI mouse spleen/pancreas assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439138	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 17.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439160	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 17.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438944	Biodistribution in NMRI mouse heart assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID574653	Drug uptake in Balb-C mouse blood assessed as compound remaining at 4-6 MBq after 30 mins by gamma counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID439175	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 3.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438919	Biodistribution in NMRI mouse kidney at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347565	Biodistribution in NMRI mouse cerebellum at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438917	Biodistribution in NMRI mouse urine at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID443216	Biostability in normal rhesus monkey assessed as intact drug level in plasma at 9 MBq, iv after 120 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID318128	Displacement of [125I]TZDM from beta amyloid protein 42	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Synthesis and evaluation of stilbenylbenzoxazole and stilbenylbenzothiazole derivatives for detecting beta-amyloid fibrils.
AID656738	Metabolic stability in Balb-C mouse blood at 21 to 32 MBq, iv after 10 mins by gamma counting	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID439643	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 32.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438931	Biodistribution in NMRI mouse spleen/pancreas at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347537	Biodistribution in NMRI mouse kidney at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439152	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 2.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID656664	Drug uptake in Balb-C mouse brain at 4 to 6 MBq, iv after 30 mins by gamma counting relative to [11C]Pittsburgh compound B	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID459781	Binding affinity to beta-amyloid plaques	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain.
AID439656	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 4.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439180	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 12 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347572	Biodistribution in NMRI mouse blood assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439670	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 57.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439703	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 10 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439165	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 42.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438927	Biodistribution in NMRI mouse liver assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438963	Drug level in NMRI mouse cerebellum assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347571	Biodistribution in NMRI mouse blood assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438954	Biodistribution in NMRI mouse cerebrum assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID443212	Biostability in normal rhesus monkey assessed as intact drug level in plasma at 9 MBq, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439684	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 17.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439663	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 22.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439177	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 6 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347560	Biodistribution in NMRI mouse stomach at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID772424	Binding affinity to human tau associated NFTs at 1 uM by fluorescence microscopy	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Imaging probes of tau pathology.
AID347553	Biodistribution in NMRI mouse heart at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID443213	Biostability in normal rhesus monkey assessed as intact drug level in plasma at 9 MBq, iv after 10 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439679	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 6 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439680	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 8 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347546	Biodistribution in NMRI mouse spleen/pancreas at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439184	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 27.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID264126	Biodistribution in brain of iv dosed ddY mouse after 2 mins	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains.
AID439696	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 0.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439633	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 3.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID445597	Biodistribution in iv dosed mouse brain after 60 mins	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
AID347559	Biodistribution in NMRI mouse stomach at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439678	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 4.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439642	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 27.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347534	Partition coefficient, log P at pH 7.4	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439167	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 52.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID594161	Binding affinity to amyloid beta 1 to 40	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain.
AID438948	Biodistribution in NMRI mouse intestine at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439169	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 65 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439140	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 27.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439691	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 52.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439187	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 42.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439172	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 0.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439654	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 2.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438951	Biodistribution in NMRI mouse stomach at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439693	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 65 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347563	Biodistribution in NMRI mouse cerebrum assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID772421	Binding affinity to human amyloid-beta plaques at 1 uM by fluorescence microscopy	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Imaging probes of tau pathology.
AID264129	Biodistribution in brain of iv dosed ddY mouse after 30 mins	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains.
AID439675	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 1.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID622840	Binding affinity to amyloid beta (1 to 42) after 3 hrs using [125I]IMSB by gamma counter method	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and evaluation of 1-(4-[¹⁸F]fluoroethyl)-7-(4'-methyl)curcumin with improved brain permeability for β-amyloid plaque imaging.
AID439146	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 57.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID265144	Displacement of [125I]IMPY from beta amyloid in human AD cortical tissue	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease.
AID438938	Biodistribution in NMRI mouse lung assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347577	Metabolic stability in NMRI mouse plasma assessed as intact drug level at 5.55 to 7.40 MBq, iv after 60 mins by RP-HPLC analysis	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439681	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 10 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347568	Biodistribution in NMRI mouse cerebellum assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439139	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 22.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439702	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 8 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439641	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 22.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439690	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 47.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439142	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 37.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438959	Biodistribution in NMRI mouse cerebellum at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439688	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 37.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439174	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 2.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439671	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 65 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439183	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 22.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439660	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 12 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439638	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 12 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439632	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 2.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID368910	Partition coefficient, log P at pH 7.4	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB.
AID347549	Biodistribution in NMRI mouse lung at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID347566	Biodistribution in NMRI mouse cerebellum at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439143	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 42.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438964	Biodistribution in NMRI mouse blood at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439664	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 27.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438932	Biodistribution in NMRI mouse spleen/pancreas assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID445596	Biodistribution in iv dosed mouse brain after 2 mins	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
AID439161	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 22.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439650	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 75 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438958	Biodistribution in NMRI mouse cerebellum at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438936	Biodistribution in NMRI mouse lung at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347536	Biodistribution in NMRI mouse urine at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439644	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 37.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347557	Biodistribution in NMRI mouse intestine at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439193	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 85 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438947	Drug level in NMRI mouse heart assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439701	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 6 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438935	Drug level in NMRI mouse spleen/pancreas assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438929	Drug level in NMRI mouse liver assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID656741	Metabolic stability in Balb-C mouse brain at 21 to 32 MBq, iv after 30 mins by gamma counting	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID438943	Biodistribution in NMRI mouse heart at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347547	Biodistribution in NMRI mouse spleen/pancreas assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID438967	Biodistribution in NMRI mouse blood assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438928	Drug level in NMRI mouse liver assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439640	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 17.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439153	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 3.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID294225	Displacement of [3H]PIB from beta amyloid in brain homogenate from Alzheimer's patient	2007	Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7	Dibenzothiazoles as novel amyloid-imaging agents.
AID439677	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 3.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439665	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 32.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439164	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 37.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439698	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 2.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439155	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 6 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439186	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 37.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438920	Biodistribution in NMRI mouse kidney assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438922	Drug level in NMRI mouse kidney assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438952	Biodistribution in NMRI mouse cerebrum at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438957	Drug level in NMRI mouse cerebrum assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438937	Biodistribution in NMRI mouse lung at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347562	Biodistribution in NMRI mouse cerebrum at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439695	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 85 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439699	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 3.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439683	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 14 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439704	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 12 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439162	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 27.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439639	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 14 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347570	Biodistribution in NMRI mouse blood at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID451844	Inhibition of amyloid beta (1-42) aggregation by thioflavin T competition binding experiment	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Push-pull benzothiazole derivatives as probes for detecting beta-amyloid plaques in Alzheimer's brains.
AID684724	Binding affinity to beta-amyloid	2012	European journal of medicinal chemistry, Nov, Volume: 57	¹⁸F-labeled 2-phenylquinoxaline derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.
AID772423	Binding affinity to human amyloid-beta plaques at 100 uM by fluorescence microscopy	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Imaging probes of tau pathology.
AID656661	Displacement of [3H]Pittsburgh compound B from human Abeta1-40 after 3 hrs by liquid scintillation counting	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID439689	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 42.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439685	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 22.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439179	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 10 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439151	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 1.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439147	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 65 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439171	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 85 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID443215	Biostability in normal rhesus monkey assessed as intact drug level in plasma at 9 MBq, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439687	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 32.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438970	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 0.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438945	Biodistribution in NMRI mouse heart assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439191	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 65 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID772422	Binding affinity to human amyloid-beta plaques at 10 uM by fluorescence microscopy	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Imaging probes of tau pathology.
AID439655	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 3.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347552	Biodistribution in NMRI mouse lung assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID308323	Displacement of [125I]TZDM from human beta amyloid fibril 1-42	2007	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14	Ferulic acid and benzothiazole dimer derivatives with high binding affinity to beta-amyloid fibrils.
AID438961	Biodistribution in NMRI mouse cerebellum assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID673978	Binding affinity to human amyloid beta plaque	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.
AID439637	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 10 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347558	Biodistribution in NMRI mouse intestine at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439653	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 1.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438930	Biodistribution in NMRI mouse spleen/pancreas at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347550	Biodistribution in NMRI mouse lung at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID443217	Biostability in normal rhesus monkey assessed as intact drug level in plasma at 9 MBq, iv after 180 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439692	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 57.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439634	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 4.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438969	Drug level in NMRI mouse blood assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439700	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 4.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439697	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 1.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439158	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 12 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID748694	Binding affinity to amyloid beta (1 to 40) (unknown origin)	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID772425	Binding affinity to human tau associated NFTs at 10 uM by fluorescence microscopy	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	Imaging probes of tau pathology.
AID347567	Biodistribution in NMRI mouse cerebellum assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID668927	Displacement of [18F]-amyvid from amyloid-beta aggregates in alzheimer's disease patient brain homogenates after 1 hr	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
AID656662	Displacement of [3H]Pittsburgh compound B from human Abeta1-42 after 3 hrs by liquid scintillation counting	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques.
AID347555	Biodistribution in NMRI mouse heart assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439649	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 65 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439686	Drug level in normal rhesus monkey white matter assessed as standard uptake value at 152.9 MBq, iv after 27.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID769546	Drug uptake in mouse brain measured at 2 mins	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID438921	Biodistribution in NMRI mouse kidney assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID265145	Lipophilicity, Log P of the compound	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease.
AID439145	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 52.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438955	Biodistribution in NMRI mouse cerebrum assessed per gram of tissue at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438925	Biodistribution in NMRI mouse liver at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438924	Biodistribution in NMRI mouse liver at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439159	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 14 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438923	Drug level in NMRI mouse kidney assessed as standard uptake value at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439673	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 85 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438946	Drug level in NMRI mouse heart assessed as standard uptake value at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439156	Drug level in normal rhesus monkey pons assessed as standard uptake value at 152.9 MBq, iv after 8 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347545	Biodistribution in NMRI mouse spleen/pancreas at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID574652	Drug uptake in Balb-C mouse blood assessed as compound remaining after 10 mins at 4-6 MBq by gamma counting	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID347535	Biodistribution in NMRI mouse urine at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID769545	Half life in baboon brain	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID439141	Drug level in normal rhesus monkey thalamus assessed as standard uptake value at 152.9 MBq, iv after 32.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439668	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 47.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438950	Biodistribution in NMRI mouse stomach at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID347539	Biodistribution in NMRI mouse kidney assessed per gram of tissue at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID439669	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 52.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439667	Drug level in normal rhesus monkey frontal cortex assessed as standard uptake value at 152.9 MBq, iv after 42.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438949	Biodistribution in NMRI mouse intestine at 3.7 MBq/mL, iv after 60 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439645	Drug level in normal rhesus monkey cerebellum assessed as standard uptake value at 152.9 MBq, iv after 42.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439176	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 4.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID439185	Drug level in normal rhesus monkey parietal cortex assessed as standard uptake value at 152.9 MBq, iv after 32.5 mins by microPET	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID438916	Biodistribution in NMRI mouse urine at 3.7 MBq/mL, iv after 2 mins by gamma counting	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID374414	Biodistribution in NMRI mouse cerebellum at 37 MBq/mL, iv after 2 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374276	Displacement of [125I]IMPY from beta-amyloid plaques in brain homogenate of patient with Alzheimer's disease by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID209521	Percent injected dose per gram of compound to Swiss-Webster mice brain was measured after 2 min of intravenous injection	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
AID438914	Displacement of [125I]IMPY from beta-amyloid plaques in Alzheimer's disease patient brain homogenate	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID374413	Biodistribution in NMRI mouse cerebrum at 37 MBq/mL, iv after 60 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374292	Biodistribution in NMRI mouse intestine at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374410	Biodistribution in NMRI mouse liver at 37 MBq/mL, iv after 2 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374407	Biodistribution in NMRI mouse blood at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID1179999	Displacement of [125I]1-Iodo-4-((4-methoxyphenoxy)methyl)benzene from amyloid beta42 (unknown origin) after 3 hrs by gamma counting	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	Radioiodinated benzyloxybenzene derivatives: a class of flexible ligands target to β-amyloid plaques in Alzheimer's brains.
AID374412	Biodistribution in NMRI mouse cerebrum at 37 MBq/mL, iv after 2 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374289	Biodistribution in NMRI mouse liver at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374293	Biodistribution in NMRI mouse cerebrum at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID718584	Displacement of thiazine red R from amyloid beta (1 to 40) aggregate after 30 mins by fluorimetric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	2-Styrylindolium based fluorescent probes visualize neurofibrillary tangles in Alzheimer's disease.
AID574648	Displacement of [3H]PiB from human amyloid beta (1-40) at 100 nM after 180 mins by liquid scintillation counter	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID314380	Displacement of [125I]TZDM from beta amyloid 42 fibril	2008	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5	Isoindol-1,3-dione and isoindol-1-one derivatives with high binding affinity to beta-amyloid fibrils.
AID374294	Biodistribution in NMRI mouse cerebrum at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374288	Biodistribution in NMRI mouse kidney at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374409	Biodistribution in NMRI mouse kidney at 37 MBq/mL, iv after 60 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID459782	Displacement of [125I-N-Methyl-4-(4-bromoanilino)phthalimide from beta-amyloid plaques isolated from Alzheimer's disease patient brain	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Novel anilinophthalimide derivatives as potential probes for beta-amyloid plaque in the brain.
AID574651	Octanol-phosphate buffered saline partition coefficient, log P of the compound at pH 7.4	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID1273178	Displacement of [125I]BOB-4 from Amyloid beta (1 to 42) (unknown origin)	2015	European journal of medicinal chemistry, Nov-02, Volume: 104	Preliminary evaluation of fluoro-pegylated benzyloxybenzenes for quantification of β-amyloid plaques by positron emission tomography.
AID374295	Biodistribution in NMRI mouse cerebellum at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374417	Biodistribution in NMRI mouse blood at 37 MBq/mL, iv after 60 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374296	Biodistribution in NMRI mouse cerebellum at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID671384	Displacement of [3H]AZD2184 from human amyloid beta(1 to 40)	2012	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13	Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as ¹⁸F-PET imaging agents for β-amyloid plaques.
AID438915	Lipophilicity, log P by RP-HPLC	2009	Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22	Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents.
AID374419	Cerebrum clearance in NMRI mouse assessed ratio of %ID in blood after 2 mins to %ID in blood after 60 mins at 37 MBq/mL, iv	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID264495	Displacement of [125I]2-(4'-dimethylaminophenyl)-6-iodoimidazo[1,2-a]pyridine from beta amyloid peptide in brain tissue at 50 uL	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Synthesis of biphenyltrienes as probes for beta-amyloid plaques.
AID230105	Ratio of percent injected dose per gram of compound to Swiss-Webster mice brain after 2 min and 30 min of intravenous injection	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
AID445593	Binding affinity to Beta amyloid aggregates in Alzheimer's disease patient brain by competitive binding assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
AID312307	Binding affinity to beta amyloid plaque in human Alzheimer's disease brain tissue	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease.
AID574649	Displacement of [3H]PiB from human amyloid beta (1-42) at 100 nM after 180 mins by liquid scintillation counter	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease.
AID374416	Biodistribution in NMRI mouse blood at 37 MBq/mL, iv after 2 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID596062	Octanol-PBS partition coefficient, log P of the compound by gamma counter	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Aromatic radiofluorination and biological evaluation of 2-aryl-6-[18F]fluorobenzothiazoles as a potential positron emission tomography imaging probe for β-amyloid plaques.
AID596061	Displacement of [3H]PIB from amyloid beta (1 to 42) aggregates in Alzheimer's disease-human brain homogenate after 3 hrs by gamma counting	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Aromatic radiofluorination and biological evaluation of 2-aryl-6-[18F]fluorobenzothiazoles as a potential positron emission tomography imaging probe for β-amyloid plaques.
AID374286	Biodistribution in NMRI mouse urine at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID19837	Apparent lipophilicity was determined	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
AID475913	Displacement of [125I]TZDM from amyloid beta (1 to 40) aggregates after 2 hrs	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for beta-amyloid plaques in Alzheimer's disease.
AID264144	Binding affinity to beta amyloid in human corpse AD brain	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains.
AID374408	Biodistribution in NMRI mouse kidney at 37 MBq/mL, iv after 2 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID594160	Displacement of [3H]BTA-1 from amyloid beta 1 to 40 by competitive binding assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain.
AID264494	Displacement of [125I](E,E)-1-iodo-2,5-bis-(3-hydroxycarbonyl-4-methoxy)styrylbenzene from beta amyloid peptide in brain tissue at 50 uL	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Synthesis of biphenyltrienes as probes for beta-amyloid plaques.
AID596060	Displacement of [125I]TZDM from amyloid beta (1 to 42) aggregates in Alzheimer's disease-human brain homogenate after 3 hrs by gamma counting	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Aromatic radiofluorination and biological evaluation of 2-aryl-6-[18F]fluorobenzothiazoles as a potential positron emission tomography imaging probe for β-amyloid plaques.
AID312308	Lipophilicity, log D at pH 7.4	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease.
AID388964	Displacement of [125I]TZDM from amyloid beta 1 to 42 aggregates	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	[(18)F]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils.
AID374415	Biodistribution in NMRI mouse cerebellum at 37 MBq/mL, iv after 60 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374290	Biodistribution in NMRI mouse liver at 37 MBq/mL, iv after 60 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID718586	Displacement of thiazine red R from human Tau aggregate expressed in Escherichia coli after 30 mins by fluorimetric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	2-Styrylindolium based fluorescent probes visualize neurofibrillary tangles in Alzheimer's disease.
AID596089	Displacement of [125I]IMPY from amyloid beta (1 to 42) after 3 hrs by gamma counting	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β-amyloid plaques in Alzheimer's brains.
AID374406	Biodistribution in NMRI mouse blood at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374285	Biodistribution in NMRI mouse urine at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID209522	Percent injected dose per gram of compound to Swiss-Webster mice brain was measured after 30 min of intravenous injection	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
AID38663	Binding affinity for Amyloid beta 1-40 aggregates in competition with [N-methyl-3H] BTA-1.	2003	Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13	Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
AID374287	Biodistribution in NMRI mouse kidney at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374291	Biodistribution in NMRI mouse intestine at 37 MBq/mL, iv after 2 mins postinjection by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
AID374411	Biodistribution in NMRI mouse liver at 37 MBq/mL, iv after 60 mins postinjection assessed per gram of tissue by gamma counting	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	125 (13.86)	29.6817
2010's	712 (78.94)	24.3611
2020's	65 (7.21)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	22 (2.41%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	43 (4.71%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	49 (5.37%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	11 (1.20%)	0.25%
Observational	0 (0.00%)	0.25%
Other	788 (86.31%)	84.16%
Other	19 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.21	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
choline [no description available]	2.05	1	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	3.18	1	0	cyclitol; hexol
hydroxide ion [no description available]	2.05	1	0	oxygen hydride	mouse metabolite
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	2.55	2	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.	2.05	1	0	amphetamines; dimethoxybenzene; organoiodine compound
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	5.7	9	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
tramiprosate tramiprosate: GABA receptor agonist and a glycosaminoglycan mimetic; has nootropic acitivity; structure; a sulfonate analog of GABA. 3-aminopropanesulfonic acid : An amino sulfonic acid that is the 3-amino derivative of propanesulfonic acid.	3.18	1	0	amino sulfonic acid; zwitterion	algal metabolite; anti-inflammatory agent; anticonvulsant; GABA agonist; nootropic agent
cgp 52411 4,5-dianilinophthalimide: structure given in first source. 4,5-dianilinophthalimide : Phthalimide substituted at the 4- and 5-positions by anilino groups.	2.05	1	0	phthalimides	geroprotector; tyrosine kinase inhibitor
benphothiamine benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.	2.13	1	0	aminopyrimidine; formamides; organic phosphate; thioester	antioxidant; immunological adjuvant; nutraceutical; protective agent; provitamin B1
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.05	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
carvedilol [no description available]	3.18	1	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.46	2	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	3.18	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	3.53	1	1	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	3.18	1	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
indoprofen Indoprofen: A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21). indoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein.	2.04	1	0	gamma-lactam; isoindoles; monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
iofetamine Iofetamine: An amphetamine analog that is rapidly taken up by the lungs and from there redistributed primarily to the brain and liver. It is used in brain radionuclide scanning with I-123.	2.13	1	0
1,2,5,8-tetrahydroxy anthraquinone 1,2,5,8-tetrahydroxy anthraquinone: structure in first source. quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions.	3.18	1	0	tetrahydroxyanthraquinone	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	3.18	1	0	benzothiazoles
tetrabenazine 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.	4.39	7	0	benzoquinolizine; cyclic ketone; tertiary amino compound
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.52	2	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
p-dimethylaminoazobenzene p-Dimethylaminoazobenzene: A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound may reasonably be anticipated to be a carcinogen. (Merck, 11th ed)	2.13	1	0	azobenzenes
methylene blue Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.	3.18	1	0	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.99	4	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.08	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.06	1	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
isoleucine Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.	2.1	1	0	aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.06	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
methyl iodide methyl iodide: RN given refers to unlabeled cpd with MF of CH3-I. iodomethane : A member of the class of iodomethanes that is methane in which one of the hydrogens is replaced by iodine.	2.06	1	0	iodomethanes; methyl halides	fumigant insecticide
tolonium chloride Tolonium Chloride: A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery.. tolonium chloride : An organic chloride salt having 3-amino-7-(dimethylamino)-2-methylphenothiazin-5-ium (tolonium) as the counterion. It is a blue nuclear counterstain that can be used to demonstrate Nissl substance and is also useful for staining mast cell granules, both in metachromatic and orthochromatic techniques.	3.18	1	0
benzothiazole benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.	2.47	2	0	benzothiazoles	environmental contaminant; plant metabolite; xenobiotic
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.13	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
thiamine pyrophosphate Thiamine Pyrophosphate: The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the PYRUVATE DEHYDROGENASE COMPLEX and the KETOGLUTARATE DEHYDROGENASE COMPLEX.. thiamine(1+) diphosphate chloride : An organic chloride salt of thiamine(1+) diphosphate.	2.17	1	0	organic chloride salt; vitamin B1
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	5.5	4	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
thiazoles [no description available]	21.65	886	24	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
12-crown-4 12-crown-4: structure in first source. 12-crown-4 : A crown ether that is cyclododecane in which the carbon atoms at positions 1, 4, 7 and 10 have been replaced by oxygen atoms.	2.1	1	0	crown ether; saturated organic heteromonocyclic parent
methyl triflate [no description available]	2.06	1	0
fluorobenzenes Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.	2.05	1	0	monofluorobenzenes	NMR chemical shift reference compound
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	5.03	11	0
congo red Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.	4.06	4	0	bis(azo) compound
azure a Azure A: RN given refers to chloride. azure A : An organic chloride salt having 3-amino-7-(dimethylamino)phenothiazin-5-ium as the counterion. It is used in making azure eosin stains for blood smear staining.	3.18	1	0
thioflavin t thioflavin T: RN given refers to chloride; structure. thioflavine T : An organic chloride salt having 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium as the counterion. It is widely used to visualise and quantify the presence of amyloids, both in vitro and in vivo.	5.17	8	0	organic chloride salt	fluorochrome; geroprotector; histological dye
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.52	2	0	f-block element atom; lanthanoid atom
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	3.69	3	0	dihydrogen
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	3.92	4	0	selegiline; terminal acetylenic compound	geroprotector
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.18	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.05	1	0	benzenes; phenyl acetates
alkenes [no description available]	2.83	3	0
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.21	1	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
thionine thionine: do not confuse with the thionins which is a class of polypeptides; RN above is for the chloride;. thionine : An organic chloride salt composed of 3,7-diaminophenothiazin-5-ium and chloride ions in a 1:1 ratio. A strongly metachromatic dye, useful for the staining of acid mucopolysaccharides. It is also a common nuclear stain and can be used for the demonstration of Nissl substance in nerve cells of the CNS.	3.18	1	0
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.18	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
1,7-phenanthroline [no description available]	5.08	12	0	phenanthroline
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	14.68	160	3	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
2,3,4-trihydroxbenzophenone 2,3,4-trihydroxbenzophenone : A benzenetriol that is benzophenone in which one of the phenyl groups is substituted by hydroxy groups at positions 2, 3, and 4. It is a redox mediator.	3.18	1	0	benzenetriol; hydroxybenzophenone	drug metabolite; EC 1.14.18.1 (tyrosinase) inhibitor; human urinary metabolite; quorum sensing inhibitor; rat metabolite
lazabemide lazabemide: structure given in first source	2.17	1	0
epicatechin (-)-epicatechin : A catechin with (2R,3R)-configuration.	3.18	1	0	catechin; polyphenol	antioxidant
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	3.4	2	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
homocysteine Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.	3.15	1	0	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
benzothiazoline [no description available]	2.08	1	0
(3h)2-carbomethoxy-3-(4-fluorophenyl)tropane (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester: RN given refers to (1R-(exo,exo))-isomer	2.17	1	0
1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane: structure in first source	2.11	1	0
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.07	1	0
dihydrotetrabenazine dihydrotetrabenazine: RN given refers to cpd without isomeric designation	4.1	5	0	isoquinolines
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.05	1	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
chrysamine g chrysamine G: structure given in first source; RN refers to disodium salt	2.46	2	0
1-oxoisoindole 1-oxoisoindole: structure	2.04	1	0
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	4.18	3	1
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	3.88	2	1	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	3.07	4	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	7.87	12	2	stilbene
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester [no description available]	3.18	1	0	methoxybenzenes; substituted aniline
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	3.18	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
raclopride Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.	2.06	1	0	salicylamides
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.07	1	0	organic sodium salt	detergent; protein denaturant
jhw 015 [no description available]	3.18	1	0	indolecarboxamide
quercetin [no description available]	2.13	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
myricetin [no description available]	3.18	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
lysophosphatidylcholines lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.	2.66	2	0	1-O-acyl-sn-glycero-3-phosphocholine
mdl 100907 Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.	2.05	1	0
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone WIN 55212-2 : A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group.	3.18	1	0	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone: G-1 was able to induce both c-fos expression and proliferation in the ERalpha-negative/GPR30-positive SKBR3 breast cancer cells, the requirement for ERalpha expression in GPR30/EGFR signaling may depend on the specific cellular context of different tumor types	3.18	1	0	agonist
2-(4-(dimethylamino)styryl)benzothiazole 2-(4-(dimethylamino)styryl)benzothiazole: structure in first source	2.05	1	0
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.08	1	0	cysteinium	fundamental metabolite
n-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane N-iodoallyl-2-carbomethoxy-3-(4-fluorophenyl)tropane: a SPECT imaging agent for viewing dopamine transporter sites; structure in first source	2.84	3	0	azabicycloalkane
technetium tc 99m pyrophosphate Technetium Tc 99m Pyrophosphate: A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.	2.25	1	0
2-(4'-methylaminophenyl)benzothiazole 2-(4'-methylaminophenyl)benzothiazole: binds amyloid-beta fibrils; structure in first source	2.05	1	0
4-(6-iodo-2-imidazo[1,2-a]pyridinyl)-N,N-dimethylaniline [no description available]	3.15	5	0	imidazoles
am 1241 AM 1241: a CB(2) receptor-selective agonist; no further information available 11/2001	3.18	1	0
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	4.38	7	0
mk-9470 MK-9470: Radiopharmaceutical; for gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding PET	2.1	1	0
bay94 9172 florbetaben ((18)F) : A member of the class of stilbenoids in which the para-hydrogens of stilbene are replaced by methylamino and 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy) groups. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease.	3.16	5	0	(18)F radiopharmaceutical; aromatic ether; polyether; secondary amino compound; stilbenoid; substituted aniline	radioactive imaging agent
scopolamine hydrobromide [no description available]	2.21	1	0
2-(4-fluorophenyl)-6-methoxy-1,3-benzothiazole [no description available]	2.05	1	0	benzothiazoles
vizamyl flutemetamol ((18)F) : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by 3-((18)F)fluoro-4-(methylamino)phenyl and hydroxy groups at positions 3 and 6 respectively. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease.	2.76	3	0	(18)F radiopharmaceutical; aromatic amine; benzothiazoles; secondary amino compound	radioactive imaging agent
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.15	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
florbenazine f 18 florbenazine F 18: a PET tracer; structure in first source	2.07	1	0
florbetapir f 18 florbetapir: a PET agent for Abeta plaques; structure in first source. florbetapir F-18 : An aromatic ether consisting of a pyridine ring substituted at position 2 by a 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy group and at position 5 and a 2-(4-methylaminophenyl)vinyl group. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease.	7.06	30	0	(18)F radiopharmaceutical; aromatic ether; organofluorine compound; pyridines; substituted aniline	radioactive imaging agent
azd4694 AZD4694: an Abeta plaque neuroimaging PET radioligand; structure in first source	4.18	3	1
glycolipids [no description available]	2.15	1	0
piperidines Piperidines: A family of hexahydropyridines.	4.16	3	1
1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-benzene 1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-benzene: structure in first source	2.83	3	0
ark 62-62 ARK 62-62: structure given in first source; RN given is for L-ascorbic acid, (SP-4-2) isomer	2.17	1	0
bf 227 2-(2-(2-dimethylaminothiazol-5-yl)ethenyl)-6-(2-(fluoro)ethoxy)benzoxazole: a putative amyloid PET imaging probe; structure in first source	4.05	2	0
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	7.53	21	0
amyloid beta-peptides [no description available]	2.04	1	0
technetium tc 99m bicisate [no description available]	2.08	1	0
cgp 52411 4,5-dianilinophthalimide: structure given in first source. 4,5-dianilinophthalimide : Phthalimide substituted at the 4- and 5-positions by anilino groups.	2.05	1	0	phthalimides	geroprotector; tyrosine kinase inhibitor
indoprofen Indoprofen: A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21). indoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein.	2.04	1	0	gamma-lactam; isoindoles; monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
dehydrothio-4-toluidine dehydrothio-4-toluidine: structure in first source	3.8	2	0
congo red Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.	2.05	1	0	bis(azo) compound
thioflavin t thioflavin T: RN given refers to chloride; structure. thioflavine T : An organic chloride salt having 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium as the counterion. It is widely used to visualise and quantify the presence of amyloids, both in vitro and in vivo.	2.46	2	0	organic chloride salt	fluorochrome; geroprotector; histological dye
thioflavin t thioflavin T cation : A benzothiazolium ion obtained by methylation of the thiazole nitrogen of 2-[4-(dimethylamino)phenyl]-6-methyl-1,3-benzothiazole; the cationic component of thioflavin T.	3.8	2	0	benzothiazolium ion
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.05	1	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
chrysamine g chrysamine G: structure given in first source; RN refers to disodium salt	2.05	1	0
2-(4-aminophenyl)benzothiazole 2-(4-aminophenyl)benzothiazole: an agent with selective profile of in vitro anti-tumour activity; structure in first source	3.8	2	0
2-(4-(dimethylamino)styryl)benzothiazole 2-(4-(dimethylamino)styryl)benzothiazole: structure in first source	2.05	1	0
2-(4'-methylaminophenyl)benzothiazole 2-(4'-methylaminophenyl)benzothiazole: binds amyloid-beta fibrils; structure in first source	4.1	3	0
4-(6-iodo-2-imidazo[1,2-a]pyridinyl)-N,N-dimethylaniline [no description available]	3.67	9	0	imidazoles
bay94 9172 florbetaben ((18)F) : A member of the class of stilbenoids in which the para-hydrogens of stilbene are replaced by methylamino and 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy) groups. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease.	2.06	1	0	(18)F radiopharmaceutical; aromatic ether; polyether; secondary amino compound; stilbenoid; substituted aniline	radioactive imaging agent
florbetapir f 18 florbetapir: a PET agent for Abeta plaques; structure in first source. florbetapir F-18 : An aromatic ether consisting of a pyridine ring substituted at position 2 by a 2-{2-[2-((18)F)fluoroethoxy]ethoxy}ethoxy group and at position 5 and a 2-(4-methylaminophenyl)vinyl group. A positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease.	2.77	3	0	(18)F radiopharmaceutical; aromatic ether; organofluorine compound; pyridines; substituted aniline	radioactive imaging agent
azd4694 AZD4694: an Abeta plaque neuroimaging PET radioligand; structure in first source	2.07	1	0

Condition	Relationship Strength	Studies	Trials
Acute Confusional Senile Dementia [description not available]	21.22	657	27
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	21.22	657	27
Amyloid Neuropathies Disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. Familial, primary (nonfamilial), and secondary forms have been described. Some familial subtypes demonstrate an autosomal dominant pattern of inheritance. Clinical manifestations include sensory loss, mild weakness, autonomic dysfunction, and CARPAL TUNNEL SYNDROME. (Adams et al., Principles of Neurology, 6th ed, p1349)	2.47	2	0
Amyloid Deposits [description not available]	13.15	123	1
Akinetic-Rigid Variant of Huntington Disease [description not available]	2.05	1	0
Huntington Disease A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)	2.05	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	12.76	51	5
Amyloid Angiopathy, Cerebral [description not available]	7.4	24	1
Cerebral Amyloid Angiopathy A heterogeneous group of sporadic or familial disorders characterized by AMYLOID deposits in the walls of small and medium sized blood vessels of CEREBRAL CORTEX and MENINGES. Clinical features include multiple, small lobar CEREBRAL HEMORRHAGE; cerebral ischemia (BRAIN ISCHEMIA); and CEREBRAL INFARCTION. Cerebral amyloid angiopathy is unrelated to generalized AMYLOIDOSIS. Amyloidogenic peptides in this condition are nearly always the same ones found in ALZHEIMER DISEASE. (from Kumar: Robbins and Cotran: Pathologic Basis of Disease, 7th ed., 2005)	7.4	24	1
Cognitive Decline [description not available]	15.1	162	5
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	8.6	47	1
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	15.1	162	5
Disease Exacerbation [description not available]	13.56	94	3
Amnesia-Memory Loss [description not available]	6.09	12	0
Amnesia Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)	6.09	12	0
MS (Multiple Sclerosis) [description not available]	4.8	10	0
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	4.8	10	0
Tooth Loss The failure to retain teeth as a result of disease or injury.	2.6	1	0
Aphasia, Primary Progressive A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)	6.35	21	0
Tauopathies Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.	3.24	5	0
DDPAC [description not available]	6.54	16	1
Frontotemporal Dementia The most common clinical form of FRONTOTEMPORAL LOBAR DEGENERATION, this dementia presents with personality and behavioral changes often associated with disinhibition, apathy, and lack of insight.	6.54	16	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	12.48	104	2
Prodromal Characteristics [description not available]	4.22	15	0
Cardiac Failure [description not available]	2.85	3	0
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	5.91	34	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.85	3	0
Frontotemporal Lobar Degeneration Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA.	3.11	4	0
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.25	1	0
Acquired-Immune Deficiency Syndrome Dementia Complex [description not available]	2.25	1	0
AIDS Dementia Complex A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)	2.25	1	0
Cardiomyopathies, Primary [description not available]	4.16	5	0
AL Amyloidosis [description not available]	2.25	1	0
Immunoglobulin Light-chain Amyloidosis A nonproliferative disorder of the PLASMA CELL characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.	2.25	1	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	4.16	5	0
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	2.25	1	0
Cortical Lewy Body Disease [description not available]	8.44	28	1
Lewy Body Disease A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)	8.44	28	1
Amyloid Neuropathy Type 1 [description not available]	2.87	3	0
Amyloid Neuropathies, Familial Inherited disorders of the peripheral nervous system associated with the deposition of AMYLOID in nerve tissue. The different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (PREALBUMIN); APOLIPOPROTEIN A-I; and GELSOLIN.	2.87	3	0
Brain Vascular Disorders [description not available]	3.2	5	0
Age-Related Memory Disorders [description not available]	10.39	36	1
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	3.2	5	0
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	10.39	36	1
Cardiac Diseases [description not available]	2.31	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.31	1	0
Cerebral Microangiopathies [description not available]	5.24	10	1
Cerebral Small Vessel Diseases Pathological processes or diseases where cerebral MICROVESSELS show abnormalities. They are often associated with aging, hypertension and risk factors for lacunar infarcts (see LACUNAR INFARCTION); LEUKOARAIOSIS; and CEREBRAL HEMORRHAGE.	5.24	10	1
Apnea, Obstructive Sleep [description not available]	2.9	3	0
Sleep Apnea, Obstructive A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)	2.9	3	0
Brain Atrophy, Circumscribed Lobar [description not available]	3.01	4	0
Pick Disease of the Brain A rare form of DEMENTIA that is sometimes familial. Clinical features include APHASIA; APRAXIA; CONFUSION; ANOMIA; memory loss; and personality deterioration. This pattern is consistent with the pathologic findings of circumscribed atrophy of the poles of the FRONTAL LOBE and TEMPORAL LOBE. Neuronal loss is maximal in the HIPPOCAMPUS, entorhinal cortex, and AMYGDALA. Some ballooned cortical neurons contain argentophylic (Pick) bodies. (From Brain Pathol 1998 Apr;8(2):339-54; Adams et al., Principles of Neurology, 6th ed, pp1057-9)	3.01	4	0
Innate Inflammatory Response [description not available]	3.94	4	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.94	4	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	4.4	19	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	14.96	136	4
Diseases, Metabolic [description not available]	2.53	2	0
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	2.53	2	0
Genetic Predisposition [description not available]	3.49	7	0
Aura [description not available]	2.55	2	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	2.55	2	0
47,XX,+21 [description not available]	5.21	10	0
Down Syndrome A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)	5.21	10	0
Acute Onset Vascular Dementia [description not available]	3.97	12	0
Dementia, Vascular An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)	3.97	12	0
Degenerative Diseases, Central Nervous System [description not available]	5.79	19	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	5.79	19	1
Cacosmia [description not available]	2.49	2	0
Brain Inflammation [description not available]	2.49	2	0
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	2.49	2	0
Diabetes Mellitus, Adult-Onset [description not available]	2.85	3	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.85	3	0
Amentia [description not available]	12.87	66	3
Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.	12.87	66	3
Alogia [description not available]	3.74	3	0
Aphasia A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.	3.74	3	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	3.51	7	0
Glucose Metabolic Disorder [description not available]	2.15	1	0
Idiopathic Parkinson Disease [description not available]	8.09	23	0
Ophthalmoplegia, Progressive Supranuclear [description not available]	3.64	8	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	8.09	23	0
Supranuclear Palsy, Progressive A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)	3.64	8	0
Benign Neoplasms, Brain [description not available]	2.51	2	0
Benign Meningeal Neoplasms [description not available]	3.22	5	0
Angioblastic Meningioma [description not available]	3.04	4	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.51	2	0
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	3.22	5	0
Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)	3.04	4	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	2.83	3	0
Apraxia [description not available]	3.36	6	0
Apraxias A group of cognitive disorders characterized by the inability to perform previously learned skills that cannot be attributed to deficits of motor or sensory function. The two major subtypes of this condition are ideomotor (see APRAXIA, IDEOMOTOR) and ideational apraxia, which refers to loss of the ability to mentally formulate the processes involved with performing an action. For example, dressing apraxia may result from an inability to mentally formulate the act of placing clothes on the body. Apraxias are generally associated with lesions of the dominant PARIETAL LOBE and supramarginal gyrus. (From Adams et al., Principles of Neurology, 6th ed, pp56-7)	3.36	6	0
Biological Clock Disturbances [description not available]	3.09	1	0
Insulin Sensitivity [description not available]	2.81	3	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.81	3	0
Asymptomatic Conditions [description not available]	8.19	11	0
Sclerosis A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.	2.17	1	0
Hakim Syndrome [description not available]	5.42	7	0
Hydrocephalus, Normal Pressure A form of compensated hydrocephalus characterized clinically by a slowly progressive gait disorder (see GAIT DISORDERS, NEUROLOGIC), progressive intellectual decline, and URINARY INCONTINENCE. Spinal fluid pressure tends to be in the high normal range. This condition may result from processes which interfere with the absorption of CSF including SUBARACHNOID HEMORRHAGE, chronic MENINGITIS, and other conditions. (From Adams et al., Principles of Neurology, 6th ed, pp631-3)	5.42	7	0
Acquired Metabolic Diseases, Brain [description not available]	2.58	2	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.55	2	0
Absence Seizure [description not available]	2.17	1	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.17	1	0
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	2.17	1	0
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	2.17	1	0
Brain Hemorrhage, Cerebral [description not available]	4.96	13	0
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	4.96	13	0
Cerebral Hemorrhage, Hypertensive [description not available]	2.21	1	0
Dyskinesia Syndromes [description not available]	3.9	2	1
Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	3.9	2	1
Recrudescence [description not available]	2.57	2	0
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	2.21	1	0
Hypersomnia, Post-Traumatic [description not available]	2.21	1	0
Brain Swelling [description not available]	2.21	1	0
Clinically Isolated CNS Demyelinating Syndrome [description not available]	3.43	2	0
Dilatation, Pathologic The condition of an anatomical structure's being dilated beyond normal dimensions.	2.21	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.21	1	0
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	3.43	2	0
Amyloidosis VI [description not available]	3.02	4	0
Leukoaraiosis Non-specific white matter changes in the BRAIN, often seen after age 65. Changes include loss of AXONS; MYELIN pallor, GLIOSIS, loss of ependymal cells, and enlarged perivascular spaces. Leukoaraiosis is a risk factor for DEMENTIA and CEREBROVASCULAR DISORDERS.	2.08	1	0
Infarct, Lacunar [description not available]	2.51	2	0
Multiple System Atrophy Syndrome [description not available]	2.48	2	0
Multiple System Atrophy A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)	2.48	2	0
Bleeding [description not available]	2.76	3	0
Hemorrhage Bleeding or escape of blood from a vessel.	2.76	3	0
Acquired Agraphia [description not available]	2.08	1	0
Basal Ganglia Diseases Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.	2.08	1	0
Abnormalities, Autosome [description not available]	6.89	4	0
Acute Brain Injuries [description not available]	2.49	2	0
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.49	2	0
Adipocere [description not available]	4.1	5	0
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	2.79	3	0
Agrammatic Broca Aphasia [description not available]	2.48	2	0
Impaired Glucose Tolerance [description not available]	2.08	1	0
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.08	1	0
Brain Hemorrhage [description not available]	2.77	3	0
Intracranial Hemorrhages Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.	2.77	3	0
Muscular Weakness [description not available]	2.08	1	0
Hypermyotonia [description not available]	2.08	1	0
Muscle Weakness A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)	2.08	1	0
Long Sleeper Syndrome [description not available]	5.3	6	0
Sleep Wake Disorders Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.	5.3	6	0
Allergic Encephalomyelitis [description not available]	2.1	1	0
CACH Syndrome [description not available]	2.1	1	0
Chronic Illness [description not available]	2.11	1	0
Apoplexy [description not available]	3.34	6	0
Anterior Circulation Transient Ischemic Attack [description not available]	2.81	3	0
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.81	3	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.11	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.11	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	3.34	6	0
Articulation Disorders Disorders of the quality of speech characterized by the substitution, omission, distortion, and addition of phonemes.	2.1	1	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.51	2	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.51	2	0
Ambulation Disorders, Neurologic [description not available]	3.01	4	0
Kahler Disease [description not available]	2.11	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.11	1	0
Leukoencephalopathy Syndrome, Posterior [description not available]	2.1	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.48	2	0
Parodontosis [description not available]	2.11	1	0
Periodontal Diseases Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.	2.11	1	0
Cataract, Membranous [description not available]	2.11	1	0
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	2.11	1	0
Hypertrophy, Right Ventricular Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.	2.13	1	0
Besnier-Boeck Disease [description not available]	2.13	1	0
Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.	2.13	1	0
ADDH [description not available]	2.11	1	0
Attention Deficit Disorder with Hyperactivity A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)	2.11	1	0
Astrocytosis [description not available]	3.9	4	0
Central Nervous System Disease [description not available]	2.13	1	0
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	2.13	1	0
Brain Disorders [description not available]	2.54	2	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	2.54	2	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.15	1	0
Blood Pressure, High [description not available]	2.51	2	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.51	2	0
Elevated ICP (Intracranial Pressure) [description not available]	2.04	1	0
Intracranial Hypertension Increased pressure within the cranial vault. This may result from several conditions, including HYDROCEPHALUS; BRAIN EDEMA; intracranial masses; severe systemic HYPERTENSION; PSEUDOTUMOR CEREBRI; and other disorders.	2.04	1	0
Day Blindness [description not available]	2.45	2	0
CJD (Creutzfeldt-Jakob Disease) [description not available]	2.05	1	0
Creutzfeldt-Jakob Syndrome A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))	2.05	1	0
Brain Emboli [description not available]	2.05	1	0
Cardiac Cancer [description not available]	2.05	1	0
Angiomyxoma [description not available]	2.05	1	0
Diseases, Peripheral Vascular [description not available]	2.05	1	0
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	2.05	1	0
Altidudinal Hemianopia [description not available]	2.05	1	0
HIV Coinfection [description not available]	2.47	2	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.05	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.47	2	0
Siderosis A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.	2.06	1	0
Inclusion Body Myopathy, Sporadic [description not available]	2.06	1	0
Myositis, Inclusion Body Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)	2.06	1	0
Anterior Horn Cell Disease [description not available]	2.07	1	0
Motor Neuron Disease Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)	2.07	1	0
Cadaver A dead body, usually a human body.	2.98	1	0
Neuritis A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include PAIN; PARESTHESIAS; PARESIS; or HYPESTHESIA.	2.06	1	0
Diseases in Twins Disorders affecting TWINS, one or both, at any age.	2.06	1	0
Adiadochokinesis [description not available]	2.06	1	0
Cerebellar Ataxia Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)	2.06	1	0
Coronary Heart Disease [description not available]	2.07	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	2.07	1	0
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	2.06	1	0
Aprosodia [description not available]	2.07	1	0
Anterior Cerebral Circulation Infarction [description not available]	2.48	2	0
Complications of Diabetes Mellitus [description not available]	2.07	1	0
Auricular Fibrillation [description not available]	2.07	1	0
Hyperlipemia [description not available]	2.07	1	0
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	2.07	1	0
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.07	1	0
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	2.48	2	0
Acalculia [description not available]	2.08	1	0
Non-fluent Primary Progressive Aphasia [description not available]	2.48	2	0
ALS - Amyotrophic Lateral Sclerosis [description not available]	2.1	1	0
Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)	2.1	1	0
Sensation Disorders Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).	2.08	1	0
Vascular Injuries [description not available]	2.08	1	0
Symptom Cluster [description not available]	2.03	1	0
Syndrome A characteristic symptom complex.	2.03	1	0
Diathesis [description not available]	2.04	1	0

2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole

Description

Cross-References

Synonyms (55)

Research Excerpts

Toxicity

Pharmacokinetics

Protein Targets (4)

Inhibition Measurements

Other Measurements

Biological Processes (136)

Molecular Functions (40)

Ceullar Components (59)

Bioassays (338)

Research

Studies (902)

Market Indicators

Research Demand Index: 8.25

Study Types

2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole

Description

Cross-References

Synonyms (55)

Research Excerpts

Toxicity

Pharmacokinetics

Protein Targets (4)

Inhibition Measurements

Other Measurements

Biological Processes (136)

Molecular Functions (40)

Ceullar Components (59)

Bioassays (338)

Research

Studies (902)

Market Indicators

Research Demand Index: 8.25

Study Types

Related Drugs (122)

Related Conditions (219)